Адипонектин в генезе атерогенной дислипидемии при метаболическом синдроме
Диссертация
Метаболический синдром характеризуется наличием адипокинового дисбаланса (повышение содержания в крови лептина и снижение — адипонек-тина), который тесно связан с различными параметрами обмена углеводов и липидов, при этом на данные взаимосвязи значительное влияние оказывает пол и масса тела. Наиболее отчетливые, обратные, связи выявлены для ади-понектина с концентрациями НЭЖК, глюкозы, инсулина… Читать ещё >
Список литературы
- Алмазов В.А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. И. Роль абдоминального ожирения в патогенезе синдрома инсулинорези-стентности. // Тер. Архив. 1999. — № 10. — С. 18 — 22.
- Гинзбург М.М., Крюков H.H. Ожирение. Влияние на развитие метаболического синдрома. Профилактика и лечение. — М.: Медпрактика-М, 2002.-128 с.
- Демидова Т.Ю., Селиванова A.B., Аметов A.C. Роль жировой ткани в развитии метаболических нарушений у больных сахарным диабетом 2-го типа в сочетании с ожирением. // Тер. Архив. 2006. — № 11. — С. 64 -69.
- Ерохина E.H. Роль инсулинорезистентности в развитии макрососуди-стых осложнений сахарного диабета 2 типа и пути ее коррекции. // Ав-тореф. дисс.. канд. мед. наук. М., 2007. — 25 с.
- Климов А.Н. Причины и условия развития атеросклероза. // В кн. Превентивная кардиология. Под ред. Г. И. Косицкого. — М.: Медицина, 1977.-С. 260−321.
- Климов А.Н., Никульчева Н. Г. Обмен липидов и липопротеинов и его нарушения. СПб.: Питер Ком, 1999. — 505 с.
- Фролова Ю.В., Агеева Е. В., Виноградова Т. В. и др. Роль активности липопротеинлипазы, гиперинсулинемии и уровня неэстерифицирован-ных жирных кислот в развитии дислипидемий. // Мед. Акад. Журн. -2005. Т. 5. — № 4. — С. 43 — 49.
- Чазова И.Е., Мычка В. Б. Метаболический синдром. М.: Медиа Медика, 2004.-166 с.
- Шестов Д.Б. Расчет холестерина липопротеидов низкой плотности в миллимолях. // Лабораторное дело. 1985. — № 6. — С. 381.
- Эпидемиология и факторы риска ишемической болезни сердца. // Под ред. А. Н. Климова. Л.: Медицина, 1989. — 176 с.
- Abbasi F., Chu J., Lamendola С. et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. // Diabetes. 2004. -Vol. 53.-P. 585 -590.
- Ahima R.A. Metabolic actions of adipocyte hormones: focus on adiponectin. ' //Obesity.-2006.-Vol. 14.-Suppl. l.-P. 9S-15S.
- Ahren В., Mansson S., Gingerich R.L., Havel P .J. Regulation of plasma lep-tin in mice: influence of age, high-fat diet, and fasting. // Am. J. Physiol. -1997. Vol. 273. — P. 113 — 120.
- Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome — a new worldwide definition. // Lancet. 2005. — Vol. 366. — P. 1059 — 1062.
- Arnri E.-Z., Teboul L., Vannier C. et al. Fatty acids regulate the expression of lipoprotein lipase gene and activity in preadipose and adipose cells. // Bi-ochem. J. 1996. — Vol. 314. — P. 541 — 546.
- Ardern C.I., Katzmarzyk P.T., Janssen I., Ross R. Discrimination of health risk by combined body mass index and waist circumference. // Obes. Res. -2003.-Vol. 11.-P. 135−142.
- Arita Y., Kihara S., Ouchi N. et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. // Biochem. Biophys. Res. Commun. 1999. — Vol. 257. — P. 79 — 83.
- Banerji M.A., Faridi N., Atluri R. et al. Body composition, visceral fat, and insulin resistance in Asian Indian man. // J. Clin. Endocrinol. Metab. 1999. -Vol. 84.-P. 137−144.
- Baratta R., Amato S., Degano C. et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and interventional studies. // J. Clin. Endocrinol. Metab. 2004. — Vol. 89.-P. 2665−2671.
- Berg A.H., Combs T.P., Du X. et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. // Nat. Med. 2001. — Vol. 7. — P. 947 -953.
- Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. // Trends. Endocrinol. Metab. -2002.-Vol. 13.-P. 84−89.
- Bjorbaek C., El-Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. // J. Biol. Chem. 1999. — Vol. 274. -P. 30 059−30 065.
- Bjursell M., Ahnmark A., Bohlooly-Y. et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. // Diabetes. 2007. — Vol. 56. — P. 583−593.
- Bluher M., Brennan A.M., Kelesidis T. et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program. // Diabetes Care. 2007. — Vol. 30. -P. 280−285.
- Bobbert T., Rochlitz H., Wegewitz U. et al. Changes of adiponectin oligomer composition by moderate weight reduction. // Diabetes. 2005. -Vol. 54.-P. 2712−2719.
- Bourgeois C.S., Wiggins D., Hems R., Gibbons G.F. VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. // Am. J. Physiol. Endocrinol. Metab. 1995. — Vol. 269. — P. E208 -E215.
- Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. // Anal. Biochem. 1976. — Vol. 72. — P. 248 — 254.
- Bruun J.M., Lihn A.S., Verdich C. et al. Regulation of adiponectin by adipose-tissue derived cytokines: in vivo and in vitro investigations in humans. //Am. J. Physiol. Endocrinol. Metab.-2003.-Vol. 285.-P. E527-E533.
- Campfield L.A., Smith F.J., Guisez Y. et al. Recombinant mouse ob protein: evidence for a peripheral signal linking adiposity and central neural networks. // Science. 1995. — Vol. 269. — P. 546 — 549.
- Carey A.L., Steinberg G.R., Macaulay S.L. et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. // Diabetes. 2006. — Vol. 55.-P. 2688−2697.
- Caro J.F., Kolaczynski J.W., Nyce M.R. et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. // Lancet. 1996. — Vol. 348. — P. 159−161.
- Ceddia R.B., Koistinen H.A., Zierath J.R., Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. // FASEB J. 2002. — Vol. 16. — P. 1163 — 1176.
- Ceddia R.B., Somwar R., Maida A. et al. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. // Diabetologia. 2005. — Vol. 48. — N. 1. — P. 132 — 139.
- Chan D.C., Watts G.F., Ng T.W.K. et al. Adiponectin and other adipocyto-kines as predictors of markers of triglyceride-rich lipoprotein metabolism. // Clin. Chem. 2005. — Vol. 51. — P. 578 — 585.
- Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more just another fat cell hormone? // Diabetes Care. 2003. — Vol. 26. — P. 2442 -2450.
- Chen G., Koyama K., Yuan X. et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. // Proc. Natl. Acad. Sci. USA. 1996. — Vol. 93. — P. 14 795 — 14 799.
- Chen H., Charlat O., Tartaglia L.A. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. // Cell. 1996. — Vol. 84. — P. 491 — 495.
- Chen H., Montagnani M., Funahashi T. et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. // J. Biol. Chem. 2003. -Vol. 278. — N. 45. — P. 45 021 — 45 026.
- Chobanian A., Bakris G., Black H. et al. Seventh report of the Joint National Committee of prevention, detection, evaluation and treatment of high blood pressure. // Hypertension. 2003. — Vol. 42. — P. 1206 — 1252.
- Choi K.M., Lee J., Lee K.W. et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. // Clin. Endocrinol. (Oxf.). 2004a. — Vol. 61. — P. 75 — 80.
- Choi K.M., Lee J., Lee K.W. et al. The associations between plasma adiponectin, ghrelin levels, and cardiovascular risk factors. // Eur. J. Endocrinol. 2004b. — Vol. 150.- P. 715−718.
- Choy L., Rosen B., Spiegelman B.M. Adipsin and an endogenous pathway of complement from adipose cells. // J. Biol. Chem. 1992. — Vol. 267. — P. 12 736- 12 741.
- Clinical i Guidelines omthe identification^ evaluation j and treatment of overweight and obesity in! adults: The evidence report. NIH publication. -1998.-N. 98 -4083.-228 p.
- Cnopp M, Havel P.J., Utzschneider K.M. et al: Relationship of adiponectim to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. // Diabetologia. 2003. — Vol: 46. — P: 459−469:
- Colditz G.A., Willett W.C., Rotnitzky A., Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. // Ann. Intern. Med. 1995. — Vol. 122. — N. 7. — P. 421 -426.
- Colombo C., Cutson J.J., Yamauchi T. et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. // Diabetes. 2002. — Vol. 51. — P. 2727 — 2733.
- Combs T.P., Berg A.H., Obici S. et al. Endogenous glucose production, is inhibited by the adipose-derived protein Acrp30i // Ji Clin. Invest. 2001. -Vol. 108.-P. 1875 — 1881.
- Combs T.P., Pajvani U.B., Berg A.M. et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated' circulatingadiponectin and improved insulin sensitivity. // Endocrinology. 2004. -Vol. 145.-P. 367−383.
- Considine R.V., Considine E.L., Williams C.J. et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. // J. Clin. Invest. 1995. — Vol. 95. — P. 2986 — 2988.
- Considine R.V., Sinha M.K., Heiman M.L. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. // N. Engl. J. Med. 1996. — Vol. 334. — P. 292 — 295.
- Daimon M., Oizumi T., Saitoh T. et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. // Diabetes Care. 2003. — Vol. 26. — P. 2015 — 2020.
- Dashti N., Williams D.L., Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. // J. Lipid Res. 1989. — Vol. 30. — P. 1365 — 1373.
- Dashti N., Wolfbauer G. Secretion of lipids, apolipoproteins, and lipoproteins by human hepatoma cell line, HepG2: effects of oleic acid and insulin. // J. Lipid Res. 1987. — Vol. 28. — P. 423 — 436.
- Debard C., Laville M., Berbe V. et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. // Diabetologia. 2004. — Vol. 47. — N. 5. — P. 917 — 925.
- Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E. et al. Serum resistin (FIZZ3) protein is increased in obese humans. // J. Clin. Endocrinol. Metab.- 2003. Vol. 88. — P. 5452 — 5455.
- Delporte M.-L., Funahashi T., Takahashi M. et al. Pre- and post-translational negative effect of P-adrenoreceptor agonists on adiponectin secretion: in vitro and in vivo studies. // Biochem. J. 2002. — Vol. 367. — P. 677 — 685.
- Delporte M.-L., Mkadem S.A.E., Quisquater M., Brichard S.M. Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice. // Am. J. Physiol. Endocrinol. Metab. — 2004.- Vol. 287. P. E446 — E453.
- Despres J.P., Ferland M., Moorjani S. et al. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese men. // Arteriosclerosis. 1989. — Vol. 9. — P. 485 -492.
- Dixon J.L., Furukawa S., Ginsberg H.N. Oleate stimulates of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. // J. Biol. Chem. 1991. — Vol. 266. -N. 8. -P. 5080−5086.
- Dobbins R.L., Szczpaniak L.S., Zhang W., McGarry J.D. Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion. // Am. J. Physiol. Endocrinol. Metab. 2003. — Vol. 284. — P. E778 — ' E787.
- Dube M.G., Beretta E., Dhillon H. et al. Central leptin gene therapy blocks high-fat diet-induced weight gain, hyperleptinemia, and hyperinsulinemia. // Diabetes.-2002.-Vol. 51.-P. 1729- 1736.
- Duncan B.B., Schmidt M.I., Pankow J.S. et al. Adiponectin and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. // Diabetes. 2004. — Vol. 53. — P. 2473 — 2478.
- Ebihara K., Ogawa Y., Masuzaki H. et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatro-phic diabetes. // Diabetes. 2001. — Vol. 50. — P. 1440 — 1448.
- Fasshauer M., Klein J., Neumann S. et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. // FEBS Lett. 2001. — Vol. 507. — P. 142 — 146.
- Fasshauer M., Klein J., Neumann S. et al. Hormonal regulation of adi-ponectin gene expression in 3T3-L1 adipocytes. // Biochem. Biophys. Res. Commun. 2002. — Vol. 290. — P. 1084 — 1089.
- Fisher F.F., Trujillo M.E., Hanif W. et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance then total serum adiponectin in Indo-Asian males. // Diabetologia. 2005. — Vol. 48. -N. 6.-P. 1084−1087.
- Flegal K.M., Carroll M.D., Ogden C.L. Prevalence and trends in obesity among US adults, 1999 2000. // JAMA. — 2002. — Vol. 288. — P. 2723 -2727.
- Folsom A.R., Kushi L.H., Anderson K.E. Associations of general and abdominal obesity with multiple health outcomes in older women. // Arch. Intern. Med. 2000. — Vol. 160.-P. 2117−2128.
- Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. // JAMA. 2002. — Vol. 287. — P. 356 — 359.
- Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparation ultracentrifuge. // Clin. Chem. 1972. — Vol. 18. — P. 499 — 509.
- Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. // J. Lipid Res. -2005. Vol. 46. — P. 1369 — 1379.
- Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. // Science. 2005. — Vol. 307.-P. 426−430.
- Furler S.M., Gan S.K., Poynten A.M. et al. Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. // Obesity. -2006. Vol. 14. — N. 2. — P. 228 — 234.
- Ginsberg H.N., Zhang Y.-L., Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia.//Obesity. 2006. — Vol. 14. — Suppl. 1. -P. 41S -49S.
- Goldberg I.J. Diabetic dyslipidemia: causes and consequences. // J. Clin. Endocrinol. Metab. 2001. — Vol. 86. — N. 3. — P. 965 — 971.
- Guo Z.K., Hensrud D.D., Johnson C. M., Jensen M.D. Regional postprandial fatty acid metabolism in different obesity phenotypes. // Diabetes. 1999. -Vol. 48.-P. 1586- 1592.
- Haffner S.N., Valdez R.A., Hazuda H.P. et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). // Diabetes. 1992. — Vol. 41. — P. 715−722.
- Halaas J.L., Boozer C., Blair-West J. et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. // Proc. Natl. Acad. Sci. USA. 1997. — Vol. 94. — P. 8878 — 8883.
- Halleux C.M., Takahashi M., Delporte M.L. et al. Secretion of adiponectinrand regulation of apMl gene expression in human visceral adipose tissue. // Biochem. Biophys. Res. Commun. 2001. — Vol. 288. — P. 1102 — 1107.
- Hanley A.J.G., Bowden D., Wagenknecht L.E. et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic His
- Hispanics and Africa-Americans. // J. Clin. Endocrinol. Metab. 2007. -Vol. 92.-P. 2665−2671.
- Hanley A .J.G., Karter A.J., Festa A. et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity. The Insulin Resistance Atherosclerosis Study. // Diabetes. 2002. — Vol. 51. — P. 2642 — 2647.
- Hardie D.G. The AMP-activated protein kinase pathway — new players upstream and downstream. // J. Cell Sci. 2004. — Vol. 117. — P. 5479 — 5487.
- Havel P.J. Update on adipocyte hormones. Regulation of energy balance and carbohydrate/lipid metabolism. // Diabetes. 2004. — Vol. 53. — Suppl. 1. -P. S143-S151.
- Heymsfleld S.B., Greenberg A.S., Fujioka K. et al. Recombinant leptin for weight loss in obese and lean adults. // JAMA. 1999. — Vol. 282. — N. 16. -P. 1568- 1575.
- Hotamisligil G.S. The role of TNFa and TNF receptors in obesity and insulin resistance. // J. Int. Med. 1999. — Vol. 245. — P. 621 — 625.
- Hotta K., Funahashi T., Arita Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. // Arterioscler. Thromb. Vase. Biol. 2000. — Vol. 20. — P. 1595 — 1599.
- Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. // J. Biol. Chem. 1996. — Vol. 271. — P. 10 697 -10 703.
- Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. // Circulation. 1983. — Vol. 67. -P. 968 — 977.
- Hukshorn C.J., Saris W.H.M., Westerterp-Plantenga M.S. et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. // J. Clin. Endocrinol. Metab. 2000. — Vol. 85. — P. 4003−4009.
- Kadota A., Hozawa A., Okamura T. et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity. NIPPON DATA90, 1990 2000. // Diabetes Care. -2007. — Vol. 30. — P. 1533 — 1538.
- Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. // En-docr. Rev. 2005. — Vol. 26. — P. 439 — 451.
- Kadowaki T., Yamauchi T., Kubota N. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. // J. Clin. Invest.-2006.-Vol. 116.-N. 7.-P. 1784- 1792.
- Kantartzis K., Fritsche A., Tschritter O. et al. The association between plasma adiponectin and insulin sensitivity in humans depends on obesity. // Ob-es. Res. -2005. -Vol. 13.-N. 10.-P. 1683 1691.
- Kantartzis K., Rittig K., Balletshofer B. et al. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. // Clin. Chem. 2006. — Vol.52.-P. 1934- 1942.
- Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. // Arch. Intern. Med. — 1989. Vol. 149.-N. 7.-P. 1514- 1520.
- Karlsson C., Lindell K., Ottosson M. et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. // J. Clin. Endocrinol. Metab. 1998. — Vol. 83. -N. 11. — P. 3925−3929.
- Kazumi T., Kawaguchi A., Hirano T. et al. Serum adiponectin is associated width high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. // Metabolism. 2004. — Vol.53.-P. 589−593.
- Kelley D.E., Goodpaster B.H. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. // Diabetes Care. 2001. — Vol. 24. -P. 933 -941.
- Kelley D.E., Williams K.V., Price J.C. et al. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. //J. Clin. Endocrinol. Metab.-2001.-Vol. 86.-P. 5412−5419.
- Kempen H.J., Imbach A.P., Giller T. et al. Secretion of apolipoproteins A-l and B by HepG2 cells: regulation by substates and metabolic inhibitors. // J. Lipid Res. 1995. — Vol. 36. — P. 1796 — 1806.
- Kern P.A., Mandic A., Eckel R.H. Regulation of lipoprotein lipase by glucose in primary cultures of isolated human adipocytes. Relevance to hypertriglyceridemia of diabetes. // Diabetes. 1987. — Vol. 36. -N. 11. — P. 1238- 1245.
- Kieffer T.J., Habener J.F. The adipoinsular axis: effects of leptin on pancreatic p-cells. // Am. J. Physiol. Endocrinol. Metab. 2000. — Vol. 278. — P. El -E14.
- Kissebah A.H., Krakower G.R. Regional adiposity and mortality. // Physiol. Rev. 1994. — Vol. 74. — N. 4. — P. 761 — 811.
- Kharroubi I., Rasschaert J., Eizirik D.L., Cnop M. Expression of adiponectin receptors in pancreatic p-cells. // Biochem. Biophys. Res. Commun. 2003. -Vol. 312.-P. 1118−1122.
- Knobler H., Benderly M., Boyko V. et al. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. // Eur. J. Endocrinol. 2004. — Vol. 154. — P. 87 — 92.
- Knutson V.P. The release of lipoproten lipase from 3T3-L1 adipocytes is regulated by microvessel endothelial cells in an insulin-dependent manner. // Endocrinology. 2000. — Vol. 141. — N. 2. — P. 693 — 701.
- Kovar J., Fejfarova V., Pelikanova T., Poledne R. Hyperglycemia downregulates total lipoprotein lipase activity in humans. // Physiol. Res. -2004.-Vol. 53.-P. 61−68.
- Krakoff J., Funahashi T., Stehouwer C.D.A. et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in .the Pima Indian. // Diabetes Care. 2003. — Vol. 26. — P. 1745 — 1751.
- Kubota N., Terauchi Y., Yamauchi T. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. // J. Biol. Chem. 2002. — Vol. 277.-P. 25 863−25 866.
- Lagrost L., Florentin E., Guyard-Dangremont V. et al. Evidence for non-esterified fatty acids as modulators of neutral lipid transfers in normolipi-demic human plasma. // Arterioscler. Thromb. Vase. Biol. 1995. — Vol. 15. -P. 1388- 1396.
- Lara-Castro C., Luo N., Wallace P. et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. // Diabetes. — 2006. Vol. 55. — P. 249−259.
- Lau D.C.W., Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atheroslcerosis. // Am. J. Physiol. Heart Circ. Physiol. 2005. -Vol. 288. — P. H2031 — H2041.
- Lewis G.F., Carpentier A., Adeli K., Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. // Endocr. Rev. 2002. — Vol. 23. — N. 2. — P. 201 — 229.
- Lewis G.F., Uffelman K.D., Szeto L.W. et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. // J. Clin. Invest. 1995. — Vol. 95. — P. 158 — 166.
- Lewis G.F., Uffelman K.D., Szeto L.W., Steiner G. Effects of acute hyperin-sulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. // Diabetes. 1993. — Vol. 42. -N. 6. — P. 833 -842.
- Leyva F., Godsland I.F., Ghatei M. et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. // Arterioscler. Thromb. Vase. Biol.-1998.-Vol. 18.-P. 928−933.
- Lihn A.S., Bruun J.M., He G. et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. // Mol. Cell. Endocrinol. 2004. — Vol. 219. — P. 9 — 15.
- Lihn A.S., Ostergard T., Nyholm B. et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. // Am. J. Physiol. Endocrinol. Metab. 2003. — Vol. 284. — P. E443 — E448.
- Lindsay R.S., Funahashi T., Hanson R.L. et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. // Lancet. 2002. -Vol. 360.-P. 57−58.
- Ma K., Cabrero A., Saha P.K. et al. Increased p-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. // J. Biol. Chem. 2002. — Vol. 277. — P. 34 758 — 34 661.
- Maeda K., Okubo K., Shimomura I. et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM-1 (adipose most abundant gene transcript 1). // Biochem. Biophys. Res. Commun. 1996. — Vol. 221. -P. 286−289.
- Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. // Nat. Med. 2002. — Vol. 8. — P. 731 -737.
- Maeda N., Takahashi M., Funahashi T. et al. PPARy ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. // Diabetes. 2001. — Vol. 50. — P. 2094 — 2099.
- Mantzoros C.S. The role of leptin in human obesity and disease: a review of current evidence. // Ann. Intern. Med. 1999. — Vol. 130. — P. 671 — 680.
- Martin L.J., Woo J.G., Daniels S.R. et al. The relationships of adiponectin with insulin and lipids are strengthed with increasing adiposity. // J. Clin. Endocrinol. Metab. 2005. — Vol. 90. — P. 4255 — 4259.
- Matsubara M., Katayose S., Maruoka S. Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. // Eur. J. Endocrinol. 2003. — Vol. 148. — P. 343 — 350.
- Matsubara M., Maruoka S., Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. // J. Clin. Endocrinol. Metab. -2002a. Vol. 87. — P. 2764 — 2769.
- Matsubara M., Maruoka S., Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. // Eur. J. Endocrinol. 2002b. — Vol. 147. — P. 173 — 180.
- Matsuura F., Oku H., Koseki M. et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. // Biochem. Biophys. Res. Commun. 2007. — Vol. 358. — P. 1091 -1095.
- Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. // Arterioscler. Thromb. Vase. Biol. 2004. — Vol. 24. -P. 29−33.
- Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. // Diabetologia. 1985. — Vol. 28. -P. 412−419.
- Meigs J.B., D’Agostino R.B., Wilson P.W. et al. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. // Diabetes. 1997. — Vol. 46. — P. 1594 — 1600.
- Meigs J.B., Mittelman M.A., Nathan D.M. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. // JAMA. 2000. — Vol. 283. — N. 2. — P. 221 — 228.
- Minokoshi Y., Kim E.B., Peroni O.D. et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. // Nature. 2002. — Vol. 415. -P. 339−343.
- Mittendorfer B., Patterson B.W., Klein S. Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. // Am. J. Clin. Nutr. 2003. — Vol. 77. — P. 573 -579.
- Mizuno A., Murakami T., Doi T., Shima K. Effect of leptin on insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat. // Regul. Pept. 2001. -Vol. 99.-P. 41 -44.
- Mokdad A.H., Ford E.S., Bowman B.A. et al. Prevalence of obesity, diabetes and obesity-related health-risk factors, 2001. // JAMA. 2003. — Vol. 289.-P. 76−79.
- Montague C.T., Farooqi I.S., Whitehead J.P. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. // Nature. — 1997. Vol. 387. — P. 903 — 908.
- Mostaza J.M., Vega G.L., Snell P., Grundy S.M. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. // J. Intern. Med. 1998. — Vol. 243. — P. 265 — 274.
- Muoio D.M., Dohm G.L., Fiedorek F.T. et al. Leptin directly alters lipid partitioning in skeletal muscle. // Diabetes. 1997. — Vol. 46. — P. 1360 — 1363.
- Murray I., Sniderman A.D., Cianflone K. Enhanced triglyceride clearance with intraperitoneal human acilation stimulating protein in C57BL/6 mice. // Am. J. Physiol. Endocrinol. Metab. 1999. — Vol. 277. — P. E474 — E480.
- Nakano Y., Tobe T., Choi-Miura N-H. et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. // J. Biochem.-1996.-Vol. 120.-P. 803−812.
- Nakashima R., Kamei N., Yamane K. et al. Decreased total and high molecular adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. // J. Clin. Endocrinol. Metab. 2006. -Vol. 91.-P. 3873−3877.
- Nawrocki A.R., Rajala M.W., Tomas E. et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor y agonists. // J. Biol. Chem. 2006. -Vol. 281.-P. 2654−2660.
- Neumeier M., Sigruener A., Eggenhofer E. et al. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. // Biochem. Biophys. Res. Commun. 2007. — Vol. 352. — P. 543 — 548.
- Ng T.W.K., Watts G.F., Farvid M.S. et al. Adipocytokines and VLDL metabolism. Independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? // Diabetes. 2005. — Vol. 54. — P. 795 — 802.
- Nishizawa H., Shimomura I., Kishida K. et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. // Diabetes. —2002. Vol. 51. — P. 2734 — 2741.
- Oral E.A., Simha V., Ruiz E. et al. Leptin-replacement therapy for lipodystrophy. // N. Engl. J. Med. 2002. — Vol. 346. — P. 570 — 578.
- Osei K., Gaillard T., Schuster D. Plasma adiponectin levels in high-risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes. // Obes. Res. 2005. — Vol. 13. — P. 179 — 185.
- Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. // Circulation.2003. Vol. 107. — P. 671 — 674.
- Parhofer K.G., Barrett P.H.R. What we have learned about VLDL and LDL metabolism from human kinetics studies. // J. Lipid Res. 2006. — Vol. 47. — P. 1620- 1630.
- Park K.G., Park K.S., Kim MJ. et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. // Diabetes Res. Clin. Pract. 2004. — Vol. 63. — P. 135 — 142.
- Patsch W., Tamai T., Schonfeld G. Effect of fatty acids on lipid and apoprotein secretion and association in hepatocyte cultures. // J. Clin. Invest. — 1983. Vol. 72. — P. 371 — 378.
- Pelleymounter M.A., Cullen M.J., Baker M.B. et al. Effects of obese gene product on body weight regulation in ob/ob mice. // Science. 1995. — Vol. 28.-P. 540−543.
- Pietzsch J., Julius U., Nitzsche S., Hanefeld M. In vivo evidence for increased apolipoprotein A-l catabolism in subjects with impared glucose tolerance. // Diabetes. 1998. — Vol. 47. — P. 1928 — 1934.
- Pykalisto O.J., Smith P.H., Brunzell J.D. Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity. // J. Clin. Invest. 1975. — Vol. 56. — N. 5. — P. 1108 -1117.
- Rajala M.W., Obici S., Scherer P.E., Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-P selectively impair insulin action on glucose production. // J. Clin. Invest. 2003. — Vol. 111. — P. 225 — 230.
- Rasmussen M.S., Lihn A.S., Pedersen S.B. et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. // Obesity. 2006. — Vol. 14. — P. 28 — 35.
- Ravussin E., Pratley R.E., Maffei M. et al. Relatively low leptin concentrations precede weight gain in Pima Indians. // Nat. Med. 1997. — Vol. 3. — P. 238 — 240.
- Reaven G.M. Role of insulin resistance in human disease. // Diabetes. -1988. Vol. 37. -P. 1595 — 1607.
- Reilly M.P., Rader D.J. The metabolic syndrome: more than the sum of its parts?//Circulation.-2003.-Vol. 108.-P. 1546- 1551.
- Ruige J.B., Ballaux D.P., Funahashi T. et al. Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders. // Am. J. Clin. Nutr. 2005. — Vol. 82. -P. 21−25.
- Ruige J.B., Dekker J.M., Blum W.F. et al. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. // Diabetes Care. 1999. — Vol. 22. — P. 1097 — 1104.
- Saad M.F., Damani S., Gingerich R.L. et al. Sexual dimorphism in plasma leptin concentration. // J. Clin. Endocrinol. Metab. 1997. — Vol. 82. — P. 579−584.
- Salas-Salvado J., Granada M., Bullo M. et al. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. // Metabolism. 2007. — Vol. 56. — P. I486 — 1492. ¦
- Satoh H., Nguyen M.T.A., Trujillo M. et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats.//Diabetes.-2005.-Vol. 54.-P. 1304- 1313.
- Scherer P.E., Williams S., Fogliano M. et al. A novel serum protein similar to Clq, produced exclusively in adipocytes. // J. Biol. Chem. — 1995. Vol. 270.-P. 26 746−26 749.
- Schulze M.B., Rimm E.B., Shai I. et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. // Diabetes Care. 2004. — Vol. 27. — P. 1680 — 1687.
- Schutte A.E., Huisman H.W., Schutte R. et al. Differences and similarities regarding adiponectin investigated in African and Caucasian women. // Eur. J. Endocrinol. 2007. — Vol. 157. — P. 181 — 188.
- Schwartz M.W., Baskin D.G., Bukowski T.R. et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. //Diabetes. 1996.-Vol. 45. — P. 531 — 535.
- Semenkovich C.F., Wims M., Noe L. et al. Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated as posttranscriptional and posttranslational levels. // J. Biol. Chem. 1989. — Vol. 264. — N. 15. — P. 9030−9038.
- Shimabukuro M., Koyama K., Chen G. et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. // Proc. Natl. Acad. Sci. USA. 1997. — Vol. 94. — P. 4637 — 4641.
- Shimomura I., Funahashi T., Takahashi M. et al. Enhanced expression of PAI-I in visceral fat. Possible contributor to vascular disease in obesity. // Nat. Med. 1996. — Vol. 2. — P. 800 — 803.
- Shklyaev S., Aslanidi G., Tennant M. et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. // Proc. Natl. Acad. Sci. USA. 2003. — Vol. 100. — P. 14 217 — 14 222.
- Sinha V., Szczepaniak L.S., Wagner A.J. et al. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. // Diabetes Care. 2003. — Vol. 26. — P. 30 — 35.
- Snehalatha C., Mukesh B., Simon M. et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. // Diabetes Care. -2003. Vol. 26. — P. 3226 — 3229.
- Snijder M.B., Heine R.J., Seidell J.C. et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in oldermen and women. The Hoorn Study. // Diabetes Care. 2006. — Vol. 29. — P. 2498−2503.
- Sparks J.D., Sparks C.E. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. // J. Biol. Chem. 1990. — Vol. 265. — N. 15. — P. 8854 — 8862.
- Spranger J., Kroke A., Mohlig M. et al. Adiponectin and protection against type 2 diabetes. // Lancet. 2003. — Vol. 361. — P. 226 — 228.
- Staiger H., Kaltenbach S., Staiger K. et al. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. // Diabetes. 2004. — Vol. 53. — P. 2195 -2201.
- Steinberg G.R., Parolin M.L., Heigenhauser G.J.F., Dyck D.J. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheralleptin resistance. // Am. J. Physiol. Endocrinol. Metab. 2002. — Vol. 283.-P. E187-E192.
- Steppan C., Bailey S., Bhat S. et al. The hormone resistin links obesity to diabetes. // Nature. 2001. — Vol. 409. — P. 307 — 312.
- Tartaglia L.A. The leptin receptor. // J. Biol. Chem. 1997. — Vol. 272. — P. 6093 — 6096.
- Tschritter O., Fritsche A., Thamer C. et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. // Diabetes. 2003. — Vol. 52. — P. 239 — 243.
- Tsuchida A., Yamauchi T., Ito Y. et al. Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. // J. Biol. Chem. 2004. — Vol. 279. — N. 29. — P. 30 817 — 30 822.
- Tyroler H.A. Coronary heart disease epidemiology in the 21st century. // Epidemiol. Rev. 2000. — Vol. 22. — P.' 7 — 13.
- Van Gaal L., Rillaerts E., Creten W., De Leeuw I. Relationship of body fat distribution pattern to atherogenic risk factors in NIDDM. Preliminary results. // Diabetes Care. 1988. — Vol. 11. — N. 2. — P. 103 — 106.
- Van Heek M., Compton D.S., France C.F. et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. // J. Clin. Invest. -1997. Vol. 99. — P. 385 — 390.
- Vozarova B., Stefan N., Lindsay R.S. et al. Low plasma adiponectin concentrations do not predict weight gain in humans. // Diabetes. 2002. — Vol. 51. — P. 2964 — 2967.
- Vozarova B., Weyer C., Hanson K. et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. // Obes. Res. — 2001. — Vol. 9.-P. 414−417.
- Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. // Endocr. Rev. 2000. — Vol. 21. — P. 697 — 738.
- Waki H., Yamauchi T., Kamon J. et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. // J. Biol". Chem. 2003. — Vol. 278. — P. 40 352−40 363.
- Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsu-linemia. // J. Clin. Endocrinol. Metab. 2001. — Vol. 86. — P. 1930 — 1935.
- World Health Organization Report. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. WHO, Geneva, 1999. — 59 p.
- Wu X., Motoshima H., Mahadev K. et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adi-ponectin in primary rat adipocytes. // Diabetes. 2003. — Vol. 52. — P. 1355 — 1363.
- Xu H., Barnes G.T., Yang K. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. // J. Clin. Invest.-2003.-Vol. 112.-P. 1821 1830.
- Yamamoto Y., Hirose H., Saito I. et al. // Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. // J. Clin. Endocrinol. Metab: 2004. — Vol. 89. — P. 87 -90.
- Yamauchi T., Kamon J., Ito Y. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. // Nature. — 2003a. — Vol. 423. P. 762−769.
- Yamauchi T., Kamon J., Minokoshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating’AMP-activated protein kinase. // Nat. Med. 2002. — Vol. 8. — N. 11. — P. 1288 — 1295.
- Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. // Nat. Med. 2001. — Vol. 7. — N. 8. — P. 941 — 946.
- Yamauchi T., Kamon J'., Waki H. et al. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. // J. Biol. Chem. 2003b. — Vol. 278. — N. 4. — P. 2461 — 2468.
- Yang W.-S., Lee W.-J., Funahashi T. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. // J. Clin. Endocrinol. Metabi -2001. Vol. 86. — P. 3815 — 3819.
- You T., Nicklas B J., Ding J. et al. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range adiposity. // J. Gerontol. A Biol. Sci. Med. Sci. 2008. — Vol. 63. — P. 414 — 419.
- Yu J.G., Javorschi S., Hevener A.L. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. // Diabetes. 2002. — Vol. 51. — P. 2968 — 2974.
- Zakrzewska K.E., Cusin I., Sainsbury A. Glucocorticoids as counterregula-tory hormones of leptin: toward an understanding of leptin resistance. // Diabetes. 1997. — Vol. 46.-P. 717−719.
- Zhang Y., Proenca R., Maffei M. et al. Positional cloning of the mouse obese gene and its human homologue. // Nature. 1994. — Vol. 372. — P. 425 -432.
- Zhou H., Song X., Briggs M. et al. Adiponectin represses gluconeogenesis independent of insulin in hepatocytes. // Biochem. Biophys. Res. Commun. 2005. — Vol. 338. — P. 793 — 799.